5EU Dry Eye Syndrome Drug Forecast and Market Analysis to 2024: Santen’s New DES drug, Ikervis will be the Main Driver for the $181 Million Market – Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Dry Eye Syndrome - 5EU Drug Forecast and Market Analysis to 2024" report to their offering. DES drug sales in the 5EU reached $181m during the base year of 2014. The launch of Santen's new DES drug, Ikervis, in 2015 will be the main driver for this significant growth in these markets. The expected arrival of pharmacotherapies into the DES market in the 5EU during the forecast period will cause the relative market s

Full Story →